Overview

Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

Status:
Not yet recruiting
Trial end date:
2025-08-30
Target enrollment:
Participant gender:
Summary
This study evaluated the safety and efficacy of SPH4336 in combination with endocrine therapy in the treatment of locally advanced or metastatic breast cancer that progressed on CDK4/6 inhibitor combined with endocrine therapy.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Shanghai Pharmaceuticals Holding Co., Ltd